Streck Joanna M, Ochalek Taylor A, Miller Mollie E, Meyer Andrew C, Badger Gary, Teneback Charlotte, Dixon Anne, Higgins Stephen T, Sigmon Stacey C
University of Vermont (UVM) Department of Psychological Science, United States.
Brown University Department of Psychiatry and Human Behavior, United States.
Prev Med Rep. 2018 Jun 30;11:176-179. doi: 10.1016/j.pmedr.2018.06.016. eCollection 2018 Sep.
Chronic obstructive pulmonary disease (COPD) is the third leading cause of death in the U.S., with the majority of COPD deaths attributable to cigarette smoking. Despite this, individuals with COPD have a higher prevalence of smoking, poorer quit rates, and higher relapse rates compared to smokers without a COPD diagnosis. We examined the feasibility of an incentives-based intervention for producing an initial period of biochemically-verified smoking abstinence among daily smokers with COPD. Participants were randomly assigned to a Contingent (n = 13) or Noncontingent (n = 16) incentives condition and visited the clinic for 14 consecutive days. Contingent participants earned vouchers with monetary value contingent on breath carbon monoxide (CO) levels during Study Days 1-5 and urinary cotinine during Days 6-14. Voucher earnings began at $9.00 and increased by $1.50 with each subsequent negative sample for maximum possible of $362.50. Noncontingent participants received vouchers of comparable value independent of smoking status. Differences between conditions varied across study days for daily smoking abstinence ( = 45.27, < 0.0001), CO (F(13, 280) = 1.95, = 0.025), and cotinine (F(13, 279) = 2.20, 0.010), with generally higher rates of abstinence and lower CO and cotinine levels observed in the Contingent vs. Noncontingent conditions. Results from this randomized pilot study support the potential efficacy of an incentives-based intervention for reducing cigarette smoking among individuals with COPD. Further research efforts should seek to promote and evaluate longer-term abstinence and associated changes in respiratory function.
慢性阻塞性肺疾病(COPD)是美国第三大死因,大多数COPD死亡归因于吸烟。尽管如此,与未被诊断为COPD的吸烟者相比,COPD患者的吸烟率更高、戒烟成功率更低且复发率更高。我们研究了一种基于激励措施的干预措施在患有COPD的每日吸烟者中产生初始阶段经生化验证的戒烟效果的可行性。参与者被随机分配到有条件(n = 13)或无条件(n = 16)激励组,并连续14天到诊所就诊。有条件组的参与者在研究第1 - 5天根据呼出气一氧化碳(CO)水平以及第6 - 14天根据尿可替宁水平获得具有货币价值的代金券。代金券收入起始为9.00美元,每次后续阴性样本增加1.50美元,最高可达362.50美元。无条件组的参与者无论吸烟状态如何都会收到价值相当的代金券。不同组之间在每日戒烟(F(13, 280) = 45.27,p < 0.0001)、CO(F(13, 280) = 1.95,p = 0.025)和可替宁(F(13, 279) = 2.20,p = 0.010)方面的差异在不同研究天数有所不同,总体上有条件组的戒烟率更高,CO和可替宁水平更低。这项随机试点研究的结果支持基于激励措施的干预措施在减少COPD患者吸烟方面的潜在效果。进一步的研究应致力于促进和评估长期戒烟以及呼吸功能的相关变化。